FDA Launches Expedited IND Pilot, Begins Accepting Applications
FDA launched a final Expedited Investigational New Drug (IND) Pilot and began accepting applications to participate until October 30, 2026. The program ena…
Impact analysis · 35/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
FDA launched a final Expedited Investigational New Drug (IND) Pilot and began accepting applications to participate until October 30, 2026. The program enables rolling pre‑IND submissions with support from Qualified Research Institutions and retains full FDA regulatory authority throughout.
Quantitative evidence
- Application deadline: October 30, 2026
- Expected to select 8–10 sponsor‑QRI pairs
- Selection criteria weightings
- Anticipated duration of pilot beyond selection
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
This pilot aims to test if rolling pre‑IND submissions with QRI input can identify and resolve issues earlier to reduce clinical holds and accelerate first‑in‑human trials.
Market context
Earlier trial initiation may shorten IL‑phase development timelines, improving efficiency for sponsors preparing first‑in‑human trials.
Legal and regulatory context
This is a non‑binding pilot and does not change statutory IND review; FDA retains authority and oversight.
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- bd91a2c54562df0e331910964afc03503c20c878cbed811fcb6f167c38b4a202
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-09-15T213011Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.